MicroRNA-200a and -200b Mediated Hepatocellular Carcinoma Cell Migration Through the Epithelial to Mesenchymal Transition Markers

Hung, Chin Sheng; Liu, Hui Hsiung; Liu, Jun Jen; Yeh, Chi‐Tai; Chang, Tung-Cheng; Wu, Chih‐Hsiung; Ho, Yuan‐Soon; Wei, Po‐Li; Chang, Yu‐Jia

doi:10.1245/s10434-012-2482-4

Cited by 44 publications

(31 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, down-regulation of miR200a is observed in HCC and that suppression of miR200a promotes tumor phenotypes of HCC cells (44). Notably, overexpression of miR-200a in HCC cells did not alter cell proliferation, but is able to decrease cell migration by increasing E-cadherin (45). These earlier studies are in support for our observations showing exogenous addition of miR-200a reduces ASB4 level.…”

Section: Discussionsupporting

confidence: 87%

Expression of ankyrin repeat and SOCS box containing 4 (ASB4) confers migration and invasion properties of hepatocellular carcinoma cells

Tsang

Man

et al. 2014

BST

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 87%

Expression of ankyrin repeat and SOCS box containing 4 (ASB4) confers migration and invasion properties of hepatocellular carcinoma cells

Tsang

Man

et al. 2014

BST

View full text Add to dashboard Cite

“…Members of the miR-200 family were shown to regulate EMT in different cell systems and play important roles in HCC migration by regulating E-cadherin expression [44]. Targeting TGF- β signalling pathway is a promising approach in cancer treatment.…”

Section: Discussionmentioning

confidence: 99%

Investigating the Pretreatment miRNA Expression Patterns of Advanced Hepatocellular Carcinoma Patients in Association with Response to TACE Treatment

El-Halawany

Ismail

Zeeneldin

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a lethal malignancy with poor prognosis and limited treatment options. Transarterial chemoembolization (TACE) using chemotherapy agents—doxorubicin and cisplatin—is an accepted treatment option for locally advanced hepatocellular carcinoma. In the current study, we analyzed the expression pattern of a selected panel of 94 miRNAs in archival samples that were collected prior to treatment from 15 Egyptian patients diagnosed with advanced hepatocelleular carcinoma. We observed an overall increase in miRNA expression in HCC samples compared with normal subjects. Out of 94 examined miRNAs, 53 were significantly upregulated while 3 miRNAs were downregulated in HCC samples compared to normal liver samples. Comparing the pretreatment miRNA expression profiles in HCC patients and the patients response to TACE treatment resulted in the identification of a set of 12 miRNAs that are significantly upregulated in nonresponders group. This miRNA panel includes miR-10a-1, miR-23a-1, miR-24, miR-26a, miR-27a, miR-30c, miR-30e, miR-106b, miR-133b, miR-199a, miR-199-3p, and miR-200b. Furthermore, we observed that a panel of 10 miRNAs was significantly associated with patients' survival status at 1 year. These results highlight the potential implications of pretreatment miRNAs expression profiling in prediction of the patients' response to TACE treatment in liver cancer.

show abstract

“…H19 accomplishes this via histone acetylation to activate the miR-200 pathway after complexing with hnRNP U/PCAF/RNAPol II [39]. The miR-200 family was found to enhance E-cadherin expression in two different HCC cell lines [101]. The miR-200 family achieved this enhancement by directly targeting E-cadherin’s transcriptional repressors, ZEB1 and ZEB2, as determined in NMuMG murine mammary epithelial cells [102].…”

Section: The Roles Of H19 In the Progression Of Liver Diseasesmentioning

confidence: 99%

“…E-cadherin expression enhancement hinders EMT in an in vitro model of EMT induced by transforming growth factor-β in NmuMG cells. E-cadherin expression also decreases motility in different cell lines derived from cancer, including HepJ5 cells, an HCC cell line [101]. Again, the H19 transcript is not fully responsible for its function in EMT, as miR-675 also plays a role.…”

Section: The Roles Of H19 In the Progression Of Liver Diseasesmentioning

confidence: 99%

Targeting H19, an Imprinted Long Non-Coding RNA, in Hepatic Functions and Liver Diseases

et al. 2017

View full text Add to dashboard Cite

H19 is a long non-coding RNA regulated by genomic imprinting through methylation at the locus between H19 and IGF2. H19 is important in normal liver development, controlling proliferation and impacting genes involved in an important network controlling fetal development. H19 also plays a major role in disease progression, particularly in hepatocellular carcinoma. H19 participates in the epigenetic regulation of many processes impacting diseases, such as activating the miR-200 pathway by histone acetylation to inhibit the epithelial-mesenchymal transition to suppress tumor metastasis. Furthermore, H19's normal regulation is disturbed in diseases, such as hepatocellular carcinoma. In this disease, aberrant epigenetic maintenance results in biallelic expression of IGF2, leading to uncontrolled cellular proliferation. This review aims to further research utilizing H19 for drug discovery and the treatment of liver diseases by focusing on both the epigenetic regulation of H19 and how H19 regulates normal liver functions and diseases, particularly by epigenetic mechanisms.

show abstract

MicroRNA-200a and -200b Mediated Hepatocellular Carcinoma Cell Migration Through the Epithelial to Mesenchymal Transition Markers

Abstract: Members of the miR-200 family (miR-200a and miR-200b) play important roles in HCC migration by regulating E-cadherin expression.

Cited by 44 publications

References 41 publications

Expression of ankyrin repeat and SOCS box containing 4 (ASB4) confers migration and invasion properties of hepatocellular carcinoma cells

Expression of ankyrin repeat and SOCS box containing 4 (ASB4) confers migration and invasion properties of hepatocellular carcinoma cells

Investigating the Pretreatment miRNA Expression Patterns of Advanced Hepatocellular Carcinoma Patients in Association with Response to TACE Treatment

Targeting H19, an Imprinted Long Non-Coding RNA, in Hepatic Functions and Liver Diseases

Contact Info

Product

Resources

About